Start-up ViGeneron announces research collaboration with Daiichi Sankyo
Evaluate vgAAV for novel ophthalmic gene therapy
19-Jan-2021 -
ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic ...
adeno-associated virus vectors
Daiichi Sankyo
eye disease
+3